1. Home
  2. IMNM vs HTFL Comparison

IMNM vs HTFL Comparison

Compare IMNM & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$19.35

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

HTFL

Heartflow Inc.

HOLD

Current Price

$35.13

Market Cap

2.5B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
HTFL
Founded
2006
2007
Country
United States
United States
Employees
N/A
843
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.5B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
IMNM
HTFL
Price
$19.35
$35.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
5
Target Price
$32.80
$38.20
AVG Volume (30 Days)
1.3M
1.2M
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
N/A
EPS
N/A
N/A
Revenue
$6,941,000.00
N/A
Revenue This Year
N/A
$27.66
Revenue Next Year
$1,127.34
$23.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.96
$20.13
52 Week High
$27.65
$41.22

Technical Indicators

Market Signals
Indicator
IMNM
HTFL
Relative Strength Index (RSI) 46.93 67.75
Support Level $19.28 $28.03
Resistance Level $23.00 $37.93
Average True Range (ATR) 0.84 1.87
MACD 0.21 0.45
Stochastic Oscillator 49.16 90.53

Price Performance

Historical Comparison
IMNM
HTFL

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About HTFL Heartflow Inc.

HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.

Share on Social Networks: